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Abstract
Background: Diethylstilbestrol (DES), a synthetic estrogen widely prescribed to pregnant women
during the 1940s70s, has been shown to cause reproductive problems in the daughters. Studies of
prenatally-exposed males have yielded conflicting results.
Methods: In data from a collaborative follow-up of three U.S. cohorts of DES-exposed sons, we
examined the relation of prenatal DES exposure to occurrence of male urogenital abnormalities.
Exposure status was determined through review of prenatal records. Mailed questionnaires (1994,
1997, 2001) asked about specified abnormalities of the urogenital tract. Risk ratios (RR) were
estimated by Cox regression with constant time at risk and control for year of birth.
Results: Prenatal DES exposure was not associated with varicocele, structural abnormalities of the
penis, urethral stenosis, benign prostatic hypertrophy, or inflammation/infection of the prostate,
urethra, or epididymus. However, RRs were 1.9 (95% confidence interval 1.13.4) for
cryptorchidism, 2.5 (1.54.3) for epididymal cyst, and 2.4 (1.54.4) for testicular inflammation/
infection. Stronger associations were observed for DES exposure that began before the 11th week
of pregnancy: RRs were 2.9 (1.65.2) for cryptorchidism, 3.5 (2.06.0) for epididymal cyst, and 3.0
(1.75.4) for inflammation/infection of testes.
Conclusion: These results indicate that prenatal exposure to DES increases risk of male
urogenital abnormalities and that the association is strongest for exposure that occurs early in
gestation. The findings support the hypothesis that endocrine disrupting chemicals may be a cause
of the increased prevalence of cryptorchidism that has been seen in recent years.
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Diethylstilbestrol (DES), a synthetic estrogen that was
widely prescribed to pregnant women during the 1940s to
1970s, has been associated with an increased prevalence
of abnormalities of the reproductive tract in women who
were exposed in utero [1]. Whether there are similar
effects in the exposed sons is still unclear and only a few
studies have appreciable numbers. Two studies found a
higher prevalence of genital tract abnormalities among
exposed men [2-5]. A third study, however, reported no
association between prenatal DES exposure and genital
tract abnormalities [6]. In a continuation of follow-up of
U.S. prospective cohorts of DES-exposed and unexposed
sons, we combined data from both of the previous pro-
spective studies discussed above and a third, previously
unexplored, cohort of exposed and unexposed men to re-
examine this question and investigate modifying effects of
the timing and dose of DES exposure.
Methods
Study design
In 1994, a collaborative follow-up study of all existing
U.S. cohorts of DES-exposed men and women was initi-
ated by the U.S. National Cancer Institute. Three cohorts
of men exposed to DES in utero were included. One com-
prised the sons of women who participated in a rand-
omized trial of DES at the University of Chicago in the
early 1950s. In the 1970s, the current addresses of these
young men were determined, after which they were fol-
lowed periodically with examinations and questionnaires
[7]. A second group included the sons of women who had
been treated in a private infertility practice near Boston
between 1943 and 1975; they have been followed by
questionnaire since 1975. The third group included men
whose mothers were identified as DES-exposed or unex-
posed by systematic review of prenatal records at the
Mayo Clinic for the period from 1939 to 1962; question-
naire follow-up of this group began in 1982 [8]. The study
protocol for the present collaborative study has been
approved by institutional review boards of all participat-
ing institutions and the National Cancer Institute.
From the three original cohorts, 229 men had never been
located, 136 had already died, and 463 had declined par-
ticipation. Thus, 3067 men (1638 exposed, 1429 unex-
posed) were eligible for the collaborative follow-up study.
All eligible men were contacted by mailed questionnaires
in 1994 and asked to participate in the collaborative
study. Questionnaires were obtained from 1156 exposed
men (71 percent) and 984 unexposed men (69 percent).
Of them, 91 percent of exposed and 94 percent of unex-
posed completed a 1997 follow-up questionnaire, and 91
percent each of exposed and unexposed completed a 2001
follow-up questionnaire.
For all three cohorts, DES exposure status was determined
by review of mothers' medical records. Information on
cumulative DES dose was available for 52 percent of
exposed men. Five grams was used as a cutpoint for "high"
versus "low" dose because the distribution of cumulative
dose was bimodal, with peaks at around 2 and 12 grams.
Timing of first exposure to DES was available for 90 per-
cent of exposed men. A cut-point of 11 weeks gestational
age was used because the male genitalia are most suscep-
tible to teratogens in this early period (the first nine weeks
of gestation) [9].
The 1994, 1997, and 2001 questionnaires included ques-
tions on demographic and lifestyle factors, reproductive
history, and medical history. Respondents were asked if
they had ever been diagnosed with any of the following
urogenital abnormalities: undescended testis, epididymal
cyst, varicocele, structural abnormality of penis, urethral
abnormality, or any other condition of the genital tract.
They were also asked if they had ever been diagnosed with
infection or inflammation of the prostate, urethra, testi-
cle, or epididymal tube.
Data analysis
We used Cox regression with constant time at risk to esti-
mate risk ratios (RRs) and 95 percent confidence (CI)
intervals for the association of DES exposure with uro-
genital outcomes [10]. All analyses were adjusted for year
of birth and cohort. SAS statistical software (version 9.1)
was used for all analyses.
Results
Most men, both exposed (78 percent) and unexposed (78
percent), reported having at least one physical examina-
tion in the 5 years prior to 1994, the year of the baseline
questionnaire. Similar proportions of exposed (18 per-
cent) and unexposed (17 percent) reported having had a
urologic examination. The age distributions of the
exposed and unexposed cohorts were similar: in 1994, the
median age was 43 in the exposed cohort and 42 in the
unexposed cohort.
Varicocele, urethral stenosis, and structural abnormalities
of the penis, including hypospadias, were not associated
with prenatal DES exposure (Table 1). In contrast, the RRs
for exposed versus unexposed men were 1.9 (95 percent
CI 1.13.4) for cryptorchidism and 2.5 (95 percent CI
1.54.3) for epididymal cyst. Only four men reported both
conditions. Elevated RRs for these outcomes were
observed in all three cohorts (data not shown).
DES exposure was not associated with the occurrence of
benign prostatic hypertrophy or with inflammation or
infection of the urethra, epididymus, or prostate. TherePage 2 of 6
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of the testes (RR = 2.5, 95 percent CI 1.54.4).
As shown in Table 2, associations of DES exposure with
cryptorchidism, epididymal cyst, and infection/inflam-
mation of the testes were stronger for men who were first
exposed before the 11th week of gestation than for men
first exposed later in gestation. Stronger associations were
also observed for cumulative exposures of five or more
grams of DES.
A previous investigation of participants in the Mayo Clinic
study reported null findings regarding a possible associa-
tion of prenatal DES exposure with risk of epididymal
cyst, cryptorchidism, or other urogenital abnormalities
[6]. DES doses were generally low in the population
served by the Mayo Clinic, and the timing of first exposure
varied greatly [8]. We carried out separate analyses among
participants from the Mayo cohort to assess whether tim-
ing of DES exposure would explain the earlier results.
Whereas there were no statistically significant associations
Table 1: DES exposure in relation to urogenital abnormalities
DES-Exposed
(N = 1197)
Unexposed (N = 1038)
Cases Cases Risk ratio* 95% Confidence interval
Urogenital abnormalities
Cryptorchidism 38 17 1.9 1.13.4
Epididymal cyst 55 19 2.5 1.54.3
Varicocele 63 61 0.9 0.61.3
Abnormality of penis† 9 7 1.1 0.43.0
Urethral stenosis 14 9 1.3 0.63.1
Inflammation of:
Prostate 81 61 1.1 0.81.6
Urethra 48 28 1.5 0.92.4
Testes 49 17 2.5 1.54.4
Epididymis 39 34 1.0 0.61.6
Benign prostatic hypertrophy 19 14 1.2 0.62.3
*Risk ratios adjusted for year of birth and cohort.
†Including hypospadias.
Table 2: Timing and dose of DES exposure in relation to urogenital abnormalities
Cases/Total Risk ratio* 95% Confidence interval
Cryptorchidism
Timing of DES exposure
Began after 11th wk 8/451 1.1 0.52.5
Began before 11th wk 29/625 2.9 1.65.2
Cumulative dose < 5 g 7/231 1.9 0.84.5
Cumulative dose ≥ 5 g 20/389 3.2 1.76.0
Epididymal cyst
Timing of DES exposure
Began after 11th wk 17/451 2.0 1.03.8
Began before 11th wk 38/625 3.5 2.06.0
Cumulative dose < 5 g 11/231 2.7 1.35.7
Cumulative dose ≥ 5 g 28/389 4.0 2.37.1
Inflammation of testes
Timing of DES exposure
Began after 11th wk 16/451 2.1 1.14.2
Began before 11th wk 30/625 3.0 1.75.4
Cumulative dose < 5 g 9/231 2.0 1.13.8
Cumulative dose ≥ 5 g 23/389 3.2 1.75.8
*Risk ratios adjusted for year of birth and cohort.Page 3 of 6
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torchidism were significantly associated with prenatal
DES exposure that began before the 11th week of gestation
(Table 3). Cumulative dose information was available for
only 20 percent of Mayo participants, and the cumulative
dose was 5 grams or higher for only one case of cryp-
torchidism and one case of epididymal cyst.
Discussion
Men who were exposed to DES in utero had an increased
prevalence of cryptorchidism, epididymal cysts, and
inflammation/infection of the testes. The associations
were strongest for exposure before the 11th week of gesta-
tion and for a cumulative dose of DES of 5 grams or more.
Because nearly all women who receive a cumulative dose
of 5 grams or greater had begun taking DES before the 11th
week of gestation, it was not possible to determine defin-
itively which of these factors was more important.
Studies of rats [11] and mice [12] given DES during preg-
nancy found that the male offspring had a higher than
expected prevalence of cryptorchidism and epididymal
cysts. The occurrence of epididymal cysts may be due to
the persistence of mullerian remnants. It has been
hypothesized that exogenous female sex hormones, acting
transplacentally, might interfere with the action of mulle-
rian inhibiting factor [13]. Normal descent of the testes is,
at least in part, under hormonal control [14]. The first
stage, transabdominal descent, occurs during the first tri-
mester of pregnancy under the influence of insulin-like
factor 3, which is inhibited by 17 β-estradiol in mice
embryonic cells. The second stage, inguinal-scrotal
descent, is induced by androgens and usually occurs dur-
ing weeks 2635. In a case-control study of boys with cryp-
torchidism, Bernstein et al. found that the mothers of
cases had higher levels of free and albumin-bound estra-
diol during pregnancy as compared with controls, but
there was no difference in total estradiol concentration
[15]. A similar study found higher levels of total estradiol
in the mothers of cases overall but did not find a differ-
ence for levels during the first trimester of pregnancy [16].
A third study also found no differences between cases and
controls in mother's total estradiol in the first trimester of
pregnancy [17]. DES is a more potent estrogen than estra-
diol and may have other chemical effects as well.
An examination study of 308 DES-exposed and 307 unex-
posed sons of women who participated in the University
of Chicago randomized trial indicated a higher prevalence
of epididymal cysts and of hypoplastic testes in exposed
relative to unexposed men [4]. Sixteen years later, a ques-
tionnaire study of the same cohort of men also indicated
an association between DES exposure and these outcomes
[5]. This study found the observed associations to be
stronger among men whose mothers DES treatment had
started less than 11 weeks after their last menstrual period
as compared with men whose mothers had begun taking
DES later in the pregnancy. Subsequent to the examina-
tion study from the Chicago cohort, a separate examina-
tion study was carried out in 265 exposed and 274
unexposed men who had been delivered at the Mayo
Clinic between 1939 and 1962 [6]. Contrary to findings
from the University of Chicago study, the Mayo Clinic
study reported no association between prenatal DES expo-
sure and epididymal cyst or anomalies of the testes
(including cryptorchidism) [6].
The present findings help to resolve previous discrepan-
cies in results. The weaker association observed in the
Mayo Clinic cohort in the present study and the conflict-
ing results from earlier studies can be explained by differ-
ences in timing and cumulative dose of DES. Women
treated at the Mayo Clinic typically took DES for a few
weeks to a few months and their median cumulative dose
was 720 mg [6]. For the University of Chicago trial,
women were instructed to begin taking DES at entry into
the trial, usually within the first trimester of pregnancy,
and continue with increasing doses until a week or two
before delivery [7]. The typical cumulative dose for this
cohort was around 11 grams. The third cohort making up
the present study consisted of offspring of women from
an infertility practice in which the usual protocol was to
take DES throughout the pregnancy, resulting in a high
cumulative dose. Therefore, the Mayo Clinic cohort differs
Table 3: Results for cohort of men born at the Mayo Clinic
Cases/Total Risk ratio* 95% Confidence interval
Cryptorchidism
Any DES exposure 17/675 1.7 0.73.8
Began after 11th week 7/347 1.3 0.53.5
Began before 11th week 9/252 2.4 1.06.2
Epididymal cyst
Any DES exposure 21/674 1.5 0.73.1
Began after 11th week 10/347 1.3 0.53.2
Began before 11th week 11/252 2.2 1.05.0
*Risk ratios adjusted for year of birth.Page 4 of 6
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were exposed before the 11th week of gestation (as shown
in Table 3) and very few were exposed to 5 grams or more.
When the analysis of Mayo Clinic sons was stratified on
timing of first exposure, it became clear that there was
indeed an association of DES exposure with occurrence of
cryptorchidism and epididymal cysts if exposure began
before the 11th week of pregnancy, and that the magnitude
of the association was similar to that observed in the over-
all study data.
Interestingly, timing of in utero exposure to DES has also
been shown to be a predictive factor for structural anom-
alies of the lower genital tract in exposed daughters. In a
study of structural anomalies of the cervix and vagina in
DES-exposed daughters, investigators found a higher
prevalence of anomalies (44 percent) in women who were
prenatally exposed to DES before the 15th week of gesta-
tion, compared to prevalences of 22 percent for weeks
1522 and 5 percent for weeks 23 and greater [18].
The chief limitation of our study is reliance on self-reports
for all outcomes. It is certainly possible that urogenital
abnormalities may be more likely to come to diagnosis
among DES-exposed men, and that DES-exposed men
may be more likely than unexposed men to remember
and report such abnormalities or inflammation. The fact
that associations were observed for only three of ten con-
ditions suggests an explanation other than reporting bias.
Furthermore, the stronger associations observed for expo-
sure that began early in pregnancy and for high cumula-
tive dose of DES would not be explained by reporting bias
since it is highly unlikely that there would be differential
reporting of outcomes according to dose or timing.
The association with inflammation/infection of the testes
may be a chance finding since we examined a number of
outcomes and did not have an a priori hypothesis for find-
ing an association with this endpoint. In addition, we did
not have information on the specific conditions or when
they occurred. It is possible that minimal structural abnor-
malities, such as minor obstructions, which may be asso-
ciated with prenatal DES exposure, could explain this
association. Further follow-up is needed to establish
whether the association with inflammation/infection of
the testes is due to chance or is causal. It is reassuring,
however, to find no evidence of an increase risk of benign
prostatic hypertrophy in the DES-exposed group.
Study strengths include the unbiased selection of exposed
and unexposed groups, medical record documentation of
exposure status, and a large sample size. The size of the
study population permitted a meaningful analysis by tim-
ing and dose, which helped to explain previously discrep-
ant findings.
Conclusion
The present results indicate that DES exposed sons have a
higher occurrence of cryptorchidism and epididymal cysts
than unexposed sons, and that the increased risk is related
to timing and dose. Fortunately, it has already been
shown that prenatal DES exposure in men does not mate-
rially affect fertility, even in men with urogenital anoma-
lies [5,19,20]. From a public health viewpoint, the
importance of these findings lies in their applicability to
the question of whether environmental factors acting as
endocrine disruptors may have a detrimental effect on the
male reproductive system. The prevalence of cryp-
torchidism appears to have increased in recent years and
it has been hypothesized that it is caused by a combina-
tion of genetic and environmental factors, including
endocrine disrupting chemicals [21-23]. Under this
hypothesis, the increased prevalence of cryptorchidism
and related conditions may be related to increased estro-
gen exposure in utero. In animal studies, exogenous estro-
gens have been shown to cause disorders of genital
development [24]. Our confirmation of an increased risk
of these conditions in men prenatally exposed to high
doses of DES lends credence to this hypothesis. As cohort
participants age, it will become possible to investigate
whether DES-exposed men have an increased risk of con-
ditions such as benign prostatic hypertrophy and prostate
cancer, which occur more often in older men.
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